Lifeline Scientific, Inc USD3.3m China order & trading update (5241J)
2015年12月18日 - 4:00PM
RNSを含む英国規制内ニュース (英語)
TIDMLSIC
RNS Number : 5241J
Lifeline Scientific, Inc
18 December 2015
Lifeline Scientific, Inc.
("Lifeline" or the "Company")
Key Distributor order from China of $3.3m
& Update on Trading
Lifeline Scientific (AIM: LSIC), the transplantation technology
company, announces receipt of a stocking order from its principal
distributor in China worth approximately US$3.3m.
The Company also announces that it expects revenues for the year
ending 31 December 2015 to be ahead of market expectations of
US$36.3m and for adjusted pre-tax profit to be materially ahead of
market expectations of US$3.4m. A further trading update will be
provided in January.
China order
This order follows on from the 2015 China Food and Drug
Administration (CFDA) regulatory approvals for the Company's full
line of branded organ preservation and transport products,
including the September approval of the global market leading
LifePort Kidney Transporter and related single-use consumable
devices.
During LifePort's regulatory review process, 21 of China's major
renal transplant centres adopted LifePort under observational
research protocols, during which time revenues of over US$3.3m were
realised by the Company and a reported 1,340 LifePort preserved
kidneys were successfully transplanted.
Following CFDA regulatory approvals, Lifeline has been working
closely with its distribution partner in China as they prepare for
a phased nationwide commercial launch during 2016 of the Company's
products to China's 169 renal transplant centres. Efforts have
focused on providing extensive clinical training, technical and
logistics support.
With China's official transplant waiting list reported at over
30,000 patients, and a reported several hundred thousand end-stage
renal and liver disease patient population driving demand, China
has potential to become a transplant market equivalent to or larger
than the US and Europe over the next five to ten years. As a key
strategic initiative, Lifeline Scientific has made significant
investments in the region since 2010 in market research and
developing key clinical and distributor relationships.
Commenting, David Kravitz, CEO of Lifeline Scientific, said: "It
has been a main focus to establish our Company's full product line
throughout Asia. China is among the largest developing transplant
markets in the World, and its Health Ministry appears fully
committed to a long term programme for achieving meaningful
advancements in the country's organ donation and transplantation
infrastructure and practices. These changes include adopting best
available technologies and protocols in order to achieve the best
outcomes for its patient population. Our proprietary LifePort
machine preservation products have a first mover advantage in this
market, and we aim to support these and our future innovations in
donor organ care becoming clinical standards of care
nationwide."
Lifeline Scientific, Inc. www.lifeline-scientific.com
David Kravitz, CEO Tel: +1 847 294 0300
Lisa Kieres, CFO Tel: +1 847 294 0300
Panmure Gordon (UK) Limited Tel: +44 (0)20 7886 2500
Freddy Crossley (Corporate
Finance)
Maisie Atkinson (Corporate
Broking)
Walbrook PR Limited Tel: +44 (0) 20 7933 8780 or lifeline@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Mike Wort Mob: +44 (0)7900 608 002
About Lifeline Scientific Inc.
Lifeline Scientific, Inc. is a Chicago-based global medical
technology company with regional offices in Brussels and Sao Paulo.
The Company's focus is the development of innovative products that
improve transplant outcomes and lower the overall costs of
transplantation. Its lead product, LifePort Kidney Transporter, is
the global market-leading medical device for hypothermic machine
preservation of donor kidneys. LifePorts and novel solutions
designed for preservation of other organs are in development, with
LifePort Liver Transporter next in line for commercial launch. For
more information please visit www.lifeline-scientific.com
About LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in
mind, LifePort Kidney Transporter is a proprietary medical device
designed to help improve kidney preservation, evaluation and
transport prior to transplantation. It has been widely studied in
clinical trials throughout the world and is the standard of care
for machine preservation of donor kidneys. Employed by surgeons in
over 206 leading transplant programmes in 29 countries, LifePorts
have successfully preserved more than 70,000 kidneys indicated for
clinical transplant. For more information please visit
www.organ-recovery.com
About LifePort Liver Transporter
LifePort Liver Transporter is modelled upon the clinically
proven technology platform of LifePort Kidney Transporter and the
Company's early HMP prototype successfully used in clinical
transplant studies by surgeons at New York-Presbyterian
Hospital/Columbia University Medical Center. LifePort Liver
Transporter and the Company's proprietary machine preservation
solution, Vasosol(R), are in the process of US and international
regulatory registrations. The system is designed to help improve
outcomes in liver transplantation by enabling the clinical use of
hypothermic machine perfusion, and has been developed in
consultation with clinical and research teams specialising in liver
transplantation at Columbia University Medical Center and the
University of Chicago. The system employs a rugged, streamlined
ergonomic design for ease of use and transportability from donor
bedside to recipient operating room. For more information please
visit: http://www.organ-recovery.com/pipeline.php
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCQVLBFELFEFBX
(END) Dow Jones Newswires
December 18, 2015 02:00 ET (07:00 GMT)
Lifeline Sci (LSE:LSIC)
過去 株価チャート
から 4 2024 まで 5 2024
Lifeline Sci (LSE:LSIC)
過去 株価チャート
から 5 2023 まで 5 2024